Update on the use of biologics in primary systemic vasculitides.


The introduction of biologic therapies, which selectively target components of the immune system, has revolutionized the treatment of rheumatoid arthritis. Anti-TNF-alpha therapy (infliximab, etanercept and adalimumab) and B-cell-depleting agents, such as rituximab, are the most widely used agents. Increased experience of the use of biologic drugs in other… (More)
DOI: 10.1586/1744666X.3.6.901


1 Figure or Table

Slides referencing similar topics